ISGlobal, HospitalClinic-Universitat de Barcelona, Barcelona, Spain.
Institute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza, Spain.
mBio. 2020 Oct 20;11(5):e02045-20. doi: 10.1128/mBio.02045-20.
UDP--acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and - and -linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate -acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from , an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for GNA1. The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria. Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate -acetyltransferase (GNA1), required for the biosynthesis of UDP--acetylglucosamine (UDP-GlcNAc), is essential for asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite , used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
UDP-乙酰葡萄糖胺(UDP-GlcNAc)是己糖胺生物合成途径的主要产物,是原生动物寄生虫的重要代谢物,因为其糖部分被掺入糖基磷脂酰肌醇(GPI)糖脂和β-和α-连接的聚糖中。顶复动物寄生虫具有与其他真核生物相当的己糖胺途径,除了葡萄糖胺-6-磷酸乙酰转移酶(GNA1)酶促步骤具有独立的进化起源并且与非顶复动物 GNA1 有显著差异。通过使用条件遗传工程,我们证明了 GNA1 对于生成 UDP-GlcNAc 池和红细胞内无性寄生虫发育的必要性。此外,我们提出了来自顶复动物寄生虫的 GNA1 同源物的 1.95 Å分辨率结构,该寄生虫是发展中国家腹泻的主要原因,作为 GNA1 的替代物。晶体的深入分析显示了存在与 GNA1 酶促活性相关的特定残基,进一步通过创建定点突变体进行了研究。实验揭示了顶复动物 GNA1 酶的独特特征,这些特征可通过靶向己糖胺途径来开发针对这些寄生虫的选择性抑制剂加以利用。这项工作强调了顶复动物 GNA1 作为抗疟疾药物靶点的潜力。顶复动物寄生虫对全球健康和经济造成重大负担。缺乏治疗方法、对现有疗法的耐药性出现以及寄生虫操纵宿主细胞和逃避免疫系统的能力突出表明,迫切需要表征新的药物靶点来治疗这些寄生虫引起的感染。我们证明,UDP-乙酰葡萄糖胺(UDP-GlcNAc)生物合成所需的葡萄糖胺-6-磷酸乙酰转移酶(GNA1)对于无性血期发育是必不可少的,并且编码该酶的基因的破坏会导致寄生虫在生命周期内迅速死亡。这里用作替代物的顶复动物寄生虫的 GNA1 同源物的高分辨率晶体结构突出显示了与人类 GNA1 的显著差异。这些差异可用于设计针对疟原虫的特异性抑制剂。